(888) 391-1315

53ab241127ee4a612ed1b0c0_Icon-arrow-top.png

ACTOS LAWSUITS

The maker of Actos has agreed to pay up to $2.4 Billion to those diagnosed with Bladder Cancer.

SEE THE SIDE EFFECTSthe actos litigation

Are you eligible to join the Actos settlement?

actos lawsuit

Actos Lawsuit SETTLEMENT

Actos was once the most popular medication available to treat type-2 diabetes. However, health experts have found that using the drug for long periods of time may cause as much as an 83 percent increase in the risk of developing bladder cancer.  Regulators have banned Actos in France and Germany; and the FDA has added strict warnings in the United States.

In recent years, more than 8,000 patients diagnosed with bladder cancer filed lawsuits against the maker of the drug, Takeda Pharmaceuticals, for failing to warn of the risks. Now, the company has agreed to pay as much as $2.4 billion to settle these claims.

Lawyers are helping complete this settlement, as well as filing new claims for those who have not yet received compensation. They can discuss your case at no cost to see if it qualifies and explain the litigation process. The time to file an Actos lawsuit is limited however by a statute of limitations, so it is important to get help soon.

Assistance is available. Speak with a patient advocate today.

Who Can File an Actos Lawsuit?

If you or a family member has been diagnosed with bladder cancer while taking Actos, now or in the past, you may qualify to be a part of the ongoing lawsuit. You may also be entitled to substantial compensation.

Researchers in Europe, Canada, and the United States have warned of studies showing an increased risk for bladder cancer among patients who took Actos for more than a year. Researchers at McGill University in Montreal proposed that long-term use of Actos may contribute to the development of bladder cancer. Experts fear that up to 10,000 patients may be affected by Actos bladder cancer. 

Risk factors also include smoking, being a male, and being a caucasian. Exposure to certain chemicals can also be a risk factor.

Bladder cancer usually begins in the cells that line the bladder, causing them to grow abnormally. The cells can develop mutations that cause them to grow out of control and form a tumor. In early stages, this tumor can usually be removed. However, even early stage bladder cancer must be monitored closely, as it tends to recur. Consequently, bladder cancer survivors often undergo follow-up tests for possible recurrence for years after treatment.

Common symptoms of  bladder cancer:

  • Frequent or painful urination
  • Blood in urine
  • Discoloration of urine
  • Back pain
  • Abdominal pain

If you have been taking Actos and have any of these symptoms, it is important to inform your doctor right away. If it has been determined that you have bladder cancer, you may be eligible for significant compensation from the drug manufacturer Takeda Pharmaceuticals. 

takeda lawsuit STATISTICS

BLADDER CANCER REPORTED TO THE FDA – 1,637 REPORTS
CASES PENDING IN FEDERAL ACTOS COURT – 3,867 REPORTS
VERDICTS AWARDED TO VICTIMS SO FAR - $40 MILLION
SALES SINCE RELEASE IN 1999 - $16 BILLION

follow us

Is There an Actos Recall?

The FDA has not recalled Actos; although, it did issue a warning on June 15, 2011. Without an actual Actos recall, however, experts suspect that some bladder cancer patients may not know the cause of their disease. 

Warnings about severe side effects began in June 2011 when the French Medicines Agency discovered a correlation between long-term Actos use and as much as a 40 percent increase in bladder cancer. At that point, France and Germany banned the drug. The U.S has not banned the drug, and short-term use appears to be safe from serious side effects.

Then, in April of 2012, Health Canada issued the results of a study showing that the risks of long-term use of Actos may be even higher than previously thought. In May 2012, McGill University in Montreal confirmed this fact, stating that the bladder cancer risk may be as high as 83 percent among long-term users of Actos.

Experts in the field estimate that up to 10,000 long term users could be affected. Many patients who have been diagnosed with bladder cancer and have used Actos have already filed claims against Takeda Pharmaceuticals. Due to the failure to warn patients of the danger of long-term use, Takeda Pharmaceuticals may be liable for the damages caused. 

actos claim information

Is There an Actos Class Action Lawsuit?

Many of the cases have been consolidated and moved to a central federal court, but they are not joined together in a class action lawsuit.

Actos patients who have developed bladder cancer have significant, ongoing problems with such severe and varied damages that it is best to file these cases individually. Individual lawsuits often result in much higher settlement amounts. 

Multidistrict Litigation Court (MDL) for Actos

In the case of Actos bladder cancer lawsuits, cases were consolidated to an Actos multidistrict litigation (MDL) court in the Western District of Louisiana under the Honorable Rebecca F. Doherty.

A total of 11 civil actions were transfered alleging that individuals using Actos have a higher risk of developing bladder cancer.

actos mdl court class action
actos case value

How Much are Actos Cases Worth?

When a large amount of people suffer moderate damage, class action lawsuits are often helpful. Combining many cases can sometimes give the group more power. Conversely, Actos patients who have developed bladder cancer have significant, ongoing problems with such severe and varied damages that it is best to file these cases individually. Individual lawsuits often yield much higher settlement amounts.

More than 1,200 people have already filed a lawsuit in the federal court, which is known as Re: Actos Products Liability Litigations, MDL 2299 U.S. District Court, Western District of Louisiana (Lafayette). The trials for these cases are scheduled to start in 2014. Other cases have been filed in California, where trials began in February 2013.

Lawsuits against large drug companies require adequate resources and experienced legal teams. Defective drug injuries also present complex cases that not every attorney can handle. It is important to select a law firm with experience in these types of cases and that can match the intense efforts of a powerful drug company.

Finding an Actos Lawyer

Defective drug lawsuits can be very complex, and are often different than normal personal injury or medical malpractice cases. For this reason, it is important to find an Actos lawyer who specializes in this type of claim.

Lawyers are still taking cases of patients who have used Actos and later developed bladder cancer or other severe side effects. However, the time to file is limited by your state's statute of limitations. Attorneys can review your records to see if you meet the qualifications necessary to prove liability of the manufacturer.

If you or a family member has been diagnosed with bladder cancer while taking Actos, now or in the past, it is important that you speak to a qualified attorney. 

The DrugNews Center encourages victims to seek lawyers with the experience and resources required for complex defective drug litigation, and only recommends law firms that are experienced with lawsuits against the manufacturer of Actos. 

For more information on the research, side effects, and litigation related to Actos and other drugs, or to speak to a lawyer, contact us today. We are available 24 hours a day, seven days a week. 

find actos attorney
view sources

Diabetes Drug Actos May Pose Bladder Cancer Risk. Health Canada. (Aril 20, 2012). Retrieved from www.cbc.ca

MDL Statistics Report - Distribution of Pending MDL Dockets by District. Judicial Panel on Multidistrict Litigation. (September 10, 2014). Retrieved from www.jpml.uscourts.gov

Feeley, J. Takeda Agrees to Pay $2.3 Billion to Settle Actos Cases. Bloomberg. (April 28, 2015). Retrieved from www.bloomberg.com

Pollack, A. Takeda Agrees to Pay $2.4 Billion to Settle Suits Over Cancer Risk of Actos. The New York Times. (April 28, 2015). Retrieved from www.nytimes.com